Cancer Research: Curations and Reporting: Aviva Lev-Ari, PhD, RN
April 20, 2014 by 2012pharmaceutical | Edit
Cancer Research: Curations and Reporting: Aviva Lev-Ari, PhD, RN
General
Lev-Ari, A. 7/5/2013, “2013 Perspective on “War on Cancer” on December 23, 1971
Lev-Ari, A. 3/24/2013, New Ecosystem of Cancer Research: Cross Institutional Team Science
Lev-Ari, A. 7/25/2013, Family History of Cancer may increase the Risk of Close Relatives developing the Same Type of Cancer as well as Different Types
Lev-Ari, A. 4/12/2013, 2013 American Cancer Research Association Award for Outstanding Achievement in Chemistry in Cancer Research: Professor Alexander Levitzki
Lev-Ari, A. 6/12/2013, Bioenergetic Mechanism: The Inverse Association of Cancer and Alzheimer’s
Lev-Ari, A. 1/12/2013, “Harnessing Personalized Medicine for Cancer Management, Prospects of Prevention and Cure: Opinions of Cancer Scientific Leaders @ http://pharmaceuticalintelligence.com“
Lev-Ari, A. 12/1/2012, Personalized Medicine: Cancer Cell Biology and Minimally Invasive Surgery (MIS)
Lev-Ari, A. 4/8/2013, Amiodarone Linked to Cancer Risk in Men
http://pharmaceuticalintelligence.com/2013/04/08/amiodarone-linked-to-cancer-risk-in-men/
Reporting
New Biomarker for Esophageal Cancer Reported in the Journal “Cancer Research”
Artificial Pancreas: A UK Biotech Invention – Potential for Replacement to Insulin Injections
Positron Emission Tomography (PET) and Near-Infrared Fluorescence Imaging: Noninvasive Imaging of Cancer Stem Cells (CSCs) monitoring of AC133+ glioblastoma in subcutaneous and intracerebral xenograft tumors
Efficacy of Ovariectomy in Presence of BRCA1 vs BRCA2 and the Risk for Ovarian Cancer
Oncologists ordered 3,752 FoundationOne clinical test: 200 cancer-related genes analysis — Revenues Climb 87% in Q4 2013
Alternative to Imaging (potentially): Urine Test developed by MIT – A Paper Diagnostics amplifies Signals from Growing Tumors to detect Cancer
Gene Therapy and the Genetic Study of Disease: @Berkeley and @UCSF – New DNA-editing technology spawns bold UC initiative as Crispr Goes Global
Alterations in the ACVR1 Gene can contribute to a Rare, typically Fatal Form of Childhood Brainstem Cancer called Diffuse Intrinsic Pontine Glioma (DIPG).
Novel Therapies for Cancer
Lev-Ari, A. 5/16/2013, AT13148 – A Novel Oral Multi-AGC Kinase Inhibitor Has Potent Antitumor Activity
Lev-Ari, A. 4/22/2013, “System Pharmacology: Using CellMiner and the NCI-60 Cancerous Cell Lines: William Reinhold, PhD”
Lev-Ari, A. 2/10/2013, Global Burden of Cancer Treatment & Women Health: Market Access & Cost Concerns
Lev-Ari, A. 11/21/2012, Response to Multiple Cancer Drugs through Regulation of TGF- Receptor Signaling: a MED12 Control
Lev-Ari, A. 10/1/2012, “Increased risks of obesity and cancer, Decreased risk of type 2 diabetes: The role of Tumor-suppressor phosphatase and tensin homologue (PTEN)”
Lev-Ari, A. 12/8/2012, Aspirin a Day Tied to Lower Cancer Mortality
http://pharmaceuticalintelligence.com/2012/08/11/1796/
Lev-Ari, A. 2/5/2013, Winning Over Cancer Progression: New Oncology Drugs to Suppress Passengers Mutations vs. Driver Mutations
Lev-Ari, A. 4/22/2013, “Molecular Profiling in Cancer Immunotherapy: Debraj Guha Thakurta, PhD”
http://pharmaceuticalintelligence.com/2013/04/22/molecular-profiling-in-cancer-immunotherapy/
Lev-Ari, A. 5/16/2013, “Immunomodulatory Therapeutic Antibodies for Cancer, August 13-15, 2013 – Boston, MA – Final Agenda”
Lev-Ari, A. 11/14/2012, GSK for Personalized Medicine using Cancer Drugs needs Alacris systems biology model to determine the in silico effect of the inhibitor in its “virtual clinical trial”
Lev-Ari, A. 10/16/2012, Personalized Pancreatic Cancer Treatment Option
http://pharmaceuticalintelligence.com/2012/10/16/personalized-pancreatic-cancer-treatment-option/
Lev-Ari, A. 7/10/12, Pfizer’s Kidney Cancer Drug Sutent Effectively caused REMISSION to Adult Acute Lymphoblastic Leukemia (ALL)
Lev-Ari, A. 7/9/2012, Sunitinib brings Adult Acute Lymphoblastic Leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade
Lev-Ari, A. 7/10/2012, REMISSION to Adult Acute Lymphoblastic Leukemia (ALL): Pfizer’s Sutent blocks FLT3 Gene Receptors
Genomics and Cancer
Lev-Ari, A. 9/18/2012, Head and Neck Cancer Studies Suggest Alternative Markers More Prognostically Useful than HPV DNA Testing
Lev-Ari, A. 10/24/2012, Pancreatic cancer genomes: Axon guidance pathway genes – aberrations revealed
Lev-Ari, A. 10/24/2012, Biomarker tool development for Early Diagnosis of Pancreatic Cancer: Van Andel Institute and Emory University
Lev-Ari, A. 4/22/2013, “DNA Methultransferases – Implications to Epigenetic Regulation and Cancer Therapy Targeting: James Shen, PhD”
Lev-Ari, A. 4/22/2013, “Genotype-based Analysis for Cancer Therapy using Large-scale Data Modeling: Nayoung Kim, PhD(c)”
Lev-Ari, A. 4/21/2013, Cancer Genomic Precision Therapy: Digitized Tumor’s Genome (WGSA) Compared with Genome-native Germ Line: Flash-frozen specimen and Formalin-fixed paraffin-embedded Specimen Needed
Lev-Ari, A. 1/13/2013, LEADERS in Genome Sequencing of Genetic Mutations for Therapeutic Drug Selection in Cancer Personalized Treatment: Part 2
Lev-Ari, A. 1/10/2013, Inspiration From Dr. Maureen Cronin’s Achievements in Applying Genomic Sequencing to Cancer Diagnostics
Lev-Ari, A. 11/1/2012, arrayMap: Genomic Feature Mining of Cancer Entities of Copy Number Abnormalities (CNAs) Data
Lev-Ari, A. 10/29/2012, Cancer Genomics – Leading the Way by Cancer Genomics Program at UC Santa Cruz
Lev-Ari, A. 9/10/2012, Comprehensive Genomic Characterization of Squamous Cell Lung Cancers
Lev-Ari, A. 5/21/2013, “Prostate Cancer Molecular Diagnostic Market – the Players are: SRI Int’l, Genomic Health w/Cleveland Clinic, Myriad Genetics w/UCSF, GenomeDx and BioTheranostics”
Lev-Ari, A. 5/16/2013, “A Blood Test to Identify Aggressive Prostate Cancer: a Discovery @ SRI International, Menlo Park, CA”
Lev-Ari, A. 5/20/2013, Salivary Gland Cancer – Adenoid Cystic Carcinoma: Mutation Patterns: Exome- and Genome-Sequencing @ Memorial Sloan-Kettering Cancer Center
Cancer Research by Cancer Type
Breast
Lev-Ari, A. 7/3/2013, MIT Scientists Identified Gene that Controls Aggressiveness in Breast Cancer Cells
Lev-Ari, A. 4/23/2013, Tamoxifen’s Effectiveness: Decrease in Tissue Density by Mammography – 50% Lower Risk of Dying from Breast Cancer
Lev-Ari, A. 1/17/2013, Mechanism involved in Breast Cancer Cell Growth: Function in Early Detection & Treatment
Lev-Ari, A. 8/14/2012, Missing Gene may drive more than a quarter of Breast Cancers
Breast/Ovarian
Lev-Ari, A. 5/20/2013, “Testing for Multiple Genetic Mutations via NGS for Patients: Very Strong Family History of Breast & Ovarian Cancer, Diagnosed at Young Ages, & Negative on BRCA Test”
Breast/Personalized Medicine
Lev-Ari, A. 12/24/2014, Breast Cancer: Genomic profiling to predict Survival: Combination of Histopathology and Gene Expression Analysis
Colon
Lev-Ari, A. 11/28/2012, PIK3CA mutation in Colorectal Cancer may serve as a Predictive Molecular Biomarker for adjuvant Aspirin therapy
Epigenetics
Lev-Ari, A. 4/12/2013, Critical Gene in Calcium Reabsorption: Variants in the KCNJ and SLC12A1 genes – Calcium Intake and Cancer Protection
Gastric
Lev-Ari, A. 10/17/2012, Stomach Cancer Subtypes Methylation-based identified by Singapore-Led Team
Gastric/Personalized Medicine
Lev-Ari, A. 12/24/2012, Gastric Cancer: Whole-genome reconstruction and mutational signatures
Skin Cancer
Lev-Ari, A. 4/24/2013, Association between Non-melanoma Skin Cancer and subsequent Primary Cancers in White Population
Prostate Cancer
Lev-Ari, A. 2/14/13, Prostate Cancer: Androgen-driven “Pathomechanism” in Early-onset Forms of the Disease
Lev-Ari, A. 7/31/2012, “Prostate Cancers Plunged After USPSTF Guidance, Will It Happen Again?”
Head & Neck
Lev-Ari, A. 1030/2012, Acoustic Neuroma, Neurinoma or Vestibular Schwannoma: Treatment Options
Lev-Ari, A. 10/30/2012, Clinical Trials on Schwannoma & Benign Intracranial Tumors Radiosurgery Treatment
Lev-Ari, A. 10/15/2012, Facial Nerve, Intracanalicular Meningiomas, Vestibular Schwannomas: Surgical Planning
Cancer and the Human Heart – Correlation between Cancer and Cardiovascular Diseases
o Causes
Lev-Ari, A. 1/8/2014, Reuben Shaw, Ph.D., a geneticist and researcher at the Salk Institute: Metabolism Influences Cancer
Lev-Ari, A. 1/8/2014, Heart Tumors: Etiology and Classification
http://pharmaceuticalintelligence.com/2014/01/08/heart-tumors-etiology-and-classification/
o Biomarkrs
Lev-Ari, A. 1/15/2014, Cancer Symptom Science: On the Mechanisms underlying the Expression of Cancer-related Symptoms
o Therapies
Lev-Ari, A. 1/8/2014, Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease
Lev-Ari, A. 1/8/2014, Radiation and Chemotherapy Therapy: The Pharmacological Risk for Developing Cardiovascular Disease
http://pharmaceuticalintelligence.com/2014/01/08/20316/
Lev-Ari, A. 1/8/2014, 3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.